Robert Henry, MD

Robert Henry, MD
 

Chief, Center for Metabolic Research
Chief, Section of Endocrinology, Metabolism & Diabetes
Veterans Affairs Healthcare System
Professor of Medicine‚ Department of Medicine
Division of Endocrinology and Metabolism
University of California‚ San Diego

How were trials designed that evaluated the effectiveness and safety of the fixed ratio combination of insulin glargine and lixisenatide, and what did we learn about titration and mitigating side effects? Video

How were trials designed that evaluated the effectiveness and safety of the fixed ratio combination of insulin glargine and lixisenatide, and what did we learn about titration and mitigating side effects?

How were the trials designed that evaluated the effectiveness and safety of the fixed ratio combination of insulin glargine and lixisenatide, and what did we learn about titration strategies and mitigating side effects of each components?
Robert Henry, MD

Robert Henry, MD

Which T2D patients will be the best candidates for the fixed ratio, combination regimens, i.e., iGlarLixi or iDegLira? And how effective and safe are these formulations at lowering HA1c levels? Video

Which T2D patients will be the best candidates for the fixed ratio, combination regimens, i.e., iGlarLixi or iDegLira? And how effective and safe are these formulations at lowering HA1c levels?

Which patients with T2D will be the most appropriate candidates for the fixed ratio, combination regimens, i.e., iGlarLixi or iDegLira? And just how effective, tolerable, and safe are these formulations at lowering HA1c levels?
Robert Henry, MD

Robert Henry, MD

Can you provide some discrete clinical and patient profiles where fixed ratio, combination regimens consisting of a long-acting insulin and GLP-1 RA should be strongly considered? Video

Can you provide some discrete clinical and patient profiles where fixed ratio, combination regimens consisting of a long-acting insulin and GLP-1 RA should be strongly considered?

Can you provide some discrete clinical and patient profiles where fixed ratio, combination regimens consisting of a long-acting insulin and GLP-1 RA should be strongly considered?
Robert Henry, MD

Robert Henry, MD

Why are the risks of hypoglycemia very low when using the fixed ratio, combination regimens? Does this have to do with slow titration or mechanistic complementarity? Video

Why are the risks of hypoglycemia very low when using the fixed ratio, combination regimens? Does this have to do with slow titration or mechanistic complementarity?

Why are the risks of hypoglycemia very low when using the fixed ratio, combination regimens? Does this have to do with slow titration or mechanistic complementarity? By what mechanism do they mitigate hypoglycemic risk?
Robert Henry, MD

Robert Henry, MD

Are there clinically relevant differences between the fixed ratio, combination regimens-- iGlarLixi or iDegLira--consisting of a long-acting insulin and GLP-1 RA? Video

Are there clinically relevant differences between the fixed ratio, combination regimens-- iGlarLixi or iDegLira--consisting of a long-acting insulin and GLP-1 RA?

Are there clinically relevant differences between the fixed ratio, combination regimens— iGlarLixi or iDegLira— consisting of a long-acting insulin and GLP-1 RA?
Robert Henry, MD

Robert Henry, MD